NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin by Lin, Chao et al.
NOXA-Induced Alterations in the Bax/Smac Axis Enhance
Sensitivity of Ovarian Cancer Cells to Cisplatin
Chao Lin
1, Xin-yu Zhao














1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, High Technological Development Zone,
Chengdu, China, 2Cancer Center, Chengdu Military General Hospital, Chengdu, China, 3Department of Pathogen Biology, Chengdu Medical College, Chengdu, China
Abstract
Ovarian cancer is the most common cause of death from gynecologic malignancy. Deregulation of p53 and/or p73-
associated apoptotic pathways contribute to the platinum-based resistance in ovarian cancer. NOXA, a pro-apoptotic BH3-
only protein, is identified as a transcription target of p53 and/or p73. In this study, we found that genetic variants of Bcl-2
proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin
are regulated mainly by p53. We further evaluated the effect of NOXA on cisplatin. NOXA induced apoptosis and sensitized
A2780s and SKOV3 cells to cisplatin in vitro and in vivo. The effects were mediated by elevated Bax expression, enhanced
caspase activation, release of Cyt C and Smac into the cytosol. Furthermore, gene silencing of Bax or Smac significantly
attenuated NOXA and/or cisplatin-induced apoptosis in chemosensitive A2780s cells, whereas overexpression of Bax or
addition of Smac-N7 peptide significantly increased NOXA and/or cisplatin-induced apoptosis in chemoresistant SKOV3
cells. To our knowledge, these data suggest a new mechanism by which NOXA chemosensitized ovarian cancer cells to
cisplatin by inducing alterations in the Bax/Smac axis. Taken together, our findings show that NOXA is potentially useful as
a chemosensitizer in ovarian cancer therapy.
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Introduction
Ovarian cancer is the most common cause of death from
gynecologic malignancy [1]. Although there are some improve-
ments, the long-term survival remains poor due to dose-dependent
toxicity, eventual tumor recurrence and emergence of drug-
resistant disease. To overcome these hurdles, investigations have
increasingly focused on new therapeutic strategies: modulation of
cellular chemosensitivity, reversing tumor resistance, and in-
creasing therapeutic effects of chemotherapy [2]. Emerging
evidences suggest that deregulated apoptosis pathway is a major
contributor to tumor initiation, progression, and development of
acquired resistance to anticancer therapies [3,4].
As a common genetic event in ovarian carcinoma, p53 mutation
is associated with resistance to platinum-based chemotherapy [5].
Recent reports have shown that p73, a member of p53 family
proteins, is a key regulator of apoptosis susceptibility to cisplatin
(Cis) in A2780 ovarian cancer cells [6,7], and that p73-dependent
transcriptional program is an important contributor to the
chemosensitivity pathway in BRCA1-deficient ovarian carcinoma
cells [8], indicating some mechanisms affecting p73 expressions
and functions may contribute to the development of resistance to
cisplatin-induced apoptosis in ovarian cancer cells [7]. All these
observations suggest that deregulation of p53-dependent and/or
p73-associated apoptotic pathways may contribute to the plati-
num-based resistance in ovarian cancer. Thus, restoration of the
p53 and/or p73 pathway by activating themselves or their
downstream targets may be an attractive avenue to improve
efficacy of anticancer therapies.
NOXA was first identified as a transcriptional target of p53 [9],
and recently it was also shown to be regulated transcriptionally by
p73 [8]. Like many Bcl-2 family proteins that translocate to
mitochondria and modulate mitochondrial function, NOXA
translocates to mitochondria and then leads to cytochrome C
(Cyt C) release and caspase-9 activation, and, ultimately, leading
to cell death [10,11]. NOXA functions through Bax and/or Bak to
induce apoptosis in some cancer cells such as Hela human
epithelial cervical cancer cells [9], melanoma cells [11], MCF-7
human breast cancer cells [12], etc. Furthermore, a recent report
showed a therapeutic potential of NOXA in treating human breast
cancer [12]. However, the role of NOXA in the therapeutic
responses of ovarian cancer cells to platinum-based anticancer
drugs remains unclear.
In this work, we first selected cisplatin-sensitive (A2780s,
IGROV1 and OAW42) and -resistant (A2780cp, OVCAR-3
and SKOV3) human ovarian cancer cell lines to test the
expression variations of prosurvival and proapoptotic Bcl-2 family
proteins. Then, we examined cisplatin-induced expression levels of
p53, p73, p21
waf1/cip1, NOXA and Bax in several human ovarian
cancer cell lines with different p53 status including A2780s (p53
wild-type, p53 WT), SKOV3 (p53 double deletion mutant, p53-/-
), OVCAR-3 (harboring mutant p53 R248Q) and A2780cp
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function) [13,14]. We found that p53, p73, p21
waf1/cip1, NOXA
and Bax were significantly induced by cisplatin in p53-wild type
A2780s cell line, but in other three p53-mutant ovarian cancer cell
lines, the expressions of p73, p21
waf1/cip1, NOXA and Bax
remained unchanged. Furthermore, the responses of NOXA and
Bax to cisplatin are regulated mainly by p53 other than p73 in
ovarian cancer cell lines. Considering the major regulatory
function of p53 on NOXA and Bax, two p53 and/or p73
downstream target genes, we further selected the p53 double
deletion mutant SKOV3 cell line as a model of intrinsic resistance
[15–17], and the p53-wild type A2780s cell line, which was
derived from a untreated patient with primary ovarian carcinoma
[17,18], as a model of intrinsic chemosensitivity, to evaluate the
effect of NOXA on the chemotherapeutic efficacy of cisplatin in
A2780s and SKOV3 ovarian cancer models in vitro and in vivo.W e
found that NOXA induces apoptosis independently of p53 in both
A2780s and SKOV3 cells, and that elevated expression of NOXA
can enhance sensitivity of ovarian cancer cells to cisplatin through
the alterations in the Bax/Smac axis. To our knowledge, we
provide new evidence for the potential application of NOXA as
a chemosensitizer in ovarian cancer therapy.
Materials and Methods
Ethics Statement
All studies involving mice were approved by the Institutional
Animal Care and Treatment Committee of State Key Laboratory
of Biotherapy, Sichuan University.
Materials
The Smac-N7 peptide (AVPIAQKPRQI-
KIWFQNRRMKWKK) were purchased from Calbiochem, Inc.
(San Diego, CA). It was modified to be cell permeable by linkage of
the COOH-terminal lysine to the arginine of an Antennapedia
homeodomain 16-mer peptide via a proline linker. The primary
antibodiesforwesternblottingareasfollows:Anti-Bcl-2(sc-130307),
anti-Bcl-xL (sc-8392), anti-Mcl-1 (sc-69839), anti-NOXA (sc-
30209), anti-p53 (DO-1), Anti-p73 (H-79), anti-p21
Waf1/Cip1 and
anti–b-actin (Santa Cruz, CA); anti-Bax N-20 (sc-493); anti–
caspase-3, anti–cleaved caspase-3, anti–caspase-9 and its cleaved
form (Cell Signaling Technology, Danvers, MA); anti-Smac (clone
FKE02, R&D Systems, Minneapolis, MN); anti-Cyt C (sc-13156),
cytochrome oxidase subunit IV (Molecular Probes).
Plasmids
Both pcDNA3.1(pc3.1) and pcDNA3.1 plasmid encoding
Human NOXA gene (pcDNA3.1-hNOXA, pc3.1-hNoxa) were
purified by two rounds of passage over EndoFree columns
(Qiagen, Chatsworth, CA), as reported previously [19]. pc3.1-
Bax constructs were generated according to our previous methods
[20].
Gene silencing with small interfering RNAs
Small interfering RNA (siRNA) oligonucleotides were pur-
chased from Dharmacon (Lafayette, CO) with sequences targeting
Bax (59-AACUGAUCAGA ACCAUCAUGG-39) and Smac (59-
AACCCUGUGUGCGGUUCCUAU-39). For Bax and Smac
shRNA construction, the Bax and Smac siRNA were cloned into
the pSilencer 2.1-U6 hygro plasmid.
Cell culture and transfection
A2780s, IGROV1, OAW42, A2780cp, OVCAR-3 and
SKOV3 human ovarian cancer cell lines were purchased from
ATCC (Manassas, VA) and grown in DMEM or RPMI 1640
culture containing 10% fetal bovine serum (FBS), respectively, at
37uC in a humidified atmosphere containing 5% CO2. Trans-
fection was performed with Lipofectamine
TM 2000 according to
the manufacturer’s instruction.
Treatments of cells in the in vitro experiments
A2780s and SKOV3 cells were treated as follows: Control, the
cells were left untreated and harvested when cultured for 72 h.
pc3.1 (empty vector), cells were transfected with pc3.1, and then
harvested at 48 h posttransfection. hNOXA, cells transfected with
pc3.1-hNOXA were harvested at 48 h posttransfection. Cisplatin,
cisplatin (5 mg/ml) was added when cells were cultured for
48 hours. 24 hours later, cells were harvested. hNOXA plus
cisplatin, cells transfected with pc3.1-hNOXA were added
cisplatin (5 mg/ml) at 24 h posttransfection. Twenty-four hours
later, cells were harvested.
For gene silencing or overexpression of Bax and Smac, the
corresponding siRNAs or plasmids were co-transfected with
pc3.1/pc3.1-NOXA plasmids into A2780s or SKOV3 cells. The
cells treated above were added cisplatin for additional 12 hours at
12 h post-transfection, and then harvested at 24 h post-trans-
fection.
Detection of hNOXA expression in vitro and in vivo
For detection of hNOXA expression in vitro, A2780s cells were
treated according to the schedules described above. The harvested
cells were used to detect hNOXA expression by RT-PCR and
western blot, respectively. The tumor tissues were collected for
detecting hNOXA expression in vivo by RT-PCR. The primers
used for amplification of hNOXA and GAPDH were as follows:
NOXA-F 59-AAGAACGCTCAACCGAGC-39and NOXA-R 59-
GGTTCCTGAGCAGAAGAGT-39; GAPDH-F 59-AATCC-
CATCACCATCTTCC-39 and GAPDH-R 59-CAT CACGC-
CACAGTTTCC-39.
Cell viability and apoptosis assays
Cell viability was assessed by MTT assay [21]. Apoptosis was
assessed as follows: detection of DNA fragmentation with the Cell
Death Detection ELISA kit (Roche Diagnostics), western blot
analysis of caspase activation, measurement of apoptotic cells by
flow cytometry (PI staining for sub-G1) and Hoechst 33258
staining. The Cell Death Detection ELISA quantified the
apoptotic cells by detecting the histone-associated DNA fragments
(mono- and oligo-nucleosomes) generated by the apoptotic cells
[20,22].
Flow cytometric analysis and hoechst 33258 staining
Flow cytometric analysis was performed to identify sub-G1
cells/apoptotic cells and to measure the percentage of sub-G1 cells
in hypotonic buffer as described previously [23]. Hoechst 33258
staining was performed accordingto the manufacturer’s instruc-
tions.
Semiquantitative RT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen).
Semiquantitative RT-PCR was done to amplify NOXA and
GAPDH.
Subcellular fractionation and western blot
Subcellular fractionation was done to obtain mitochondrial and
cytosolic fractions as previously described [24]. Total cell lysates
NOXA-Induced Alterations in Bax/Smac Axis
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subfractionation lysates were used for western blot analysis.
Animal tumor models and treatment
A2780s and SKOV3 cells (2610
6 cells) were implanted s.c. into
the right flanks of 6- to 8-week-old female nude mice, respectively.
To explore the therapeutic efficacy of NOXA plus cisplatin, we
treated the mice on day 10 after the implantation of tumor cells,
when tumor diameter reached ,5 mm in diameter. The mice
were randomly divided into 5 groups (5 mice per group) and
treated with: (a).100 ml PBS; (b).10 mg pc3.1 plasmid/30 mg
liposome complexes in 100 ml PBS; (c).10 mg pc3.1 -hNoxa
plasmid/30 mg liposome complexes in 100 ml PBS; (d).100 mlo f
0.1 mg cisplatin (5 mg/kg body weight); (e).10 mg pc3.1-hNoxa
plasmid/30 mg liposome complexes in 100 ml PBS and 100 mlo f
0.1 mg cisplatin. The mice were treated with DNA-liposome
complex by intravenous administration via the tail vein twice
a week, and cisplatin by intraperitoneal route once a week for 4
weeks. Tumor volumes were calculated by the following formula:
tumor volume (mm
3)=0.526length (mm)6width (mm)6width
(mm) [26]. The tumor tissues were collected for TUNEL
experiments.
Terminal deoxynucleotidyl-transferase-mediated dUTP
nick end labeling (TUNEL) analysis
TUNEL was performed with an In situ Cell Death Detection
Kit (Roche). Cell apoptosis was quantified by determining the
percentage of positively stained cells for all of the nuclei in 20
randomly chosen fields/section at 2006 magnification. Slides of
the apoptosis studies were quantified in a blind manner by two
independent reviewers two different times.
Statistical analyses
The statistical analysis was performed with SPSS software
(version 17.0 for Windows). All the values were expressed as means
6 SD. ANOVA and Tukey–Kramer multiple comparison test
were used in comparisons. Survival curves were constructed
according to the Kaplan-Meier method. Statistical significance
was determined by the log-rank test. p value,0.05 were
considered significant. Error bars represent the SEM unless
otherwise indicated.
Results
Genetic variants among the cisplatin-sensitive and -
resistant ovarian cancer cells
Western blotting analysis showed that cisplatin-sensitive
(A2780s, IGROV1 and OAW42) cell lines express relatively low
endogenous levels of Bcl-2, Bcl-xL and Mcl-1 while cisplatin-
resistant (A2780cp, OVCAR-3 and SKOV3) cell lines were on the
contrary. In contrast to prosurvival Bcl-2 family proteins, the levels
of proapoptotic Bak and Bax in A2780s, IGROV1 and OAW42
cell lines are higher than those in A2780cp, OVCAR-3 and
SKOV3 cell lines (Figure 1A).
We further examined cisplatin-induced expression levels of p53,
p73, p21
waf1/cip1, NOXA and Bax in several human ovarian
cancer cell lines with different p53 status including A2780s (p53
WT), SKOV3 (p53-/-), OVCAR-3 (harboring mutant p53
R248Q) and A2780cp (containing p53 wild-type gene sequence
but showing loss of p53 function). All the indicated cells were
treated with 5 mg/ml cisplatin for 24 hr. As shown in figure 1B
and C, p53, p73, p21
waf1/cip1, NOXA and Bax were found to be
significantly induced by cisplatin in p53-wild type A2780s cell line,
but in other three p53-mutant cisplatin-resistant OVCAR-3,
A2780cp and SKOV3 cell lines, the expressions of p73, p21
waf1/
cip1, NOXA and Bax remained unchanged. Furthermore, the level
of endogenous Bax in cisplatin-resistant OVCAR-3, A2780cp and
SKOV3 cell lines is very low (figure 1B and C). These results
indicate that the responses of NOXA and Bax to cisplatin are
regulated mainly by p53 other than p73 in ovarian cancer cell
lines.
Reduced viability of ovarian cancer cells in vitro by
hNOXA and cisplatin
The pro-apoptotic function of NOXA and lack of NOXA
induction in intrinsically cisplatin-resistant SKOV3 (p53-/-)
ovarian cells prompted us to investigate whether overexpression
of NOXA suppresses ovarian cancer cell growth. Overexpression
of hNOXA in transfected A2780s cells was confirmed by RT-PCR
(Figure 2A) and western blotting analysis (Figure 2B), respectively.
Considering that NOXA functions downstream of the p53-
mediated apoptotic pathway, and that the cytotoxic action of
cisplatin is mediated by DNA damage, which, in turn, transacti-
vates target genes (e.g.p53AIP, PUMA, NOXA) to cause
apoptosis, we predicts that elevated NOXA expression can
sensitize ovarian cancer cells to cisplatin. To test this hypothesis,
we first treated A2780s cells with cisplatin at indicated concentra-
tions, with a 24- or 48-hr interval, and found that the dose of IC50
of cisplatin ranged from 5 mg/ml to 10 mg/ml (Figure 2C). Then,
we treated cells with cisplatin at a suboptimal dose (5 mg/ml), with
a 24/48-hour interval, according to the various schedules as
described in Meterials and Methods. After treatment, viability of
cells was determined by MTT assay. As shown in figure 2D,
compared with the control, either hNOXA or cisplatin signifi-
cantly reduced A2780s cell viability by 41%/47% (P,0.001) and
43%/49% (P,0.001), respectively. hNOXA plus cisplatin very
significantly reduced A2780s cell viability by 68%/76%
(P,0.001). In p53-deficient SKOV3 cells, compared with the
pc3.1 control, hNOXA also significantly reduced cell viability
(P,0.001) while cisplatin showed only a slight, but not statistically
significant effect on SKOV3 cell growth (24 h, p=0.874; 48 h,
p=0.921). However, the combination of hNOXA and cisplatin
very significantly reduced SKOV3 cell viability by 65%/68%
(P,0.001) (Figure 2E).
Induction of apoptosis of ovarian cancer cells in vitro by
hNOXA and cisplatin
The quantitative assessment of sub-G1 cells by flow cytometry
was used to estimate the number of apoptotic cells. As shown in
figure 3A, in cisplatin-sensitive A2780s cells, the apoptotic cells
accounted for 34.6% in hNOXA-treated group versus 15.6% in
pcDNA3.1-treated group and 8.7% in control group. The
apoptotic cells accounted for 63.6% in the combination group
versus 48.3% in cisplatin-treated group. These results suggested
that either cisplatin or hNOXA alone significantly induced
apoptosis of A2780s cells, and hNOXA plus cisplatin further
augmented the induction of apoptosis. Similar results were
obtained in intrinsically resistant SKOV3 cells except that cisplatin
alone was found to have little ability to induce apoptosis of
SKOV3 cells (Figure 3B).
Apoptosis was further evaluated by Hoechst 33258 staining.
Similar to the above results, in both A2780s and SKOV3 cells, the
number of condensed nuclei (intact or fragmented), which are
characteristic of apoptosis, in the combination group were
observed than that in hNOXA- or cisplatin-treated cells. There
was no significantly condensed nuclei in medium only- and pc3.1-
NOXA-Induced Alterations in Bax/Smac Axis
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treated SKOV3 cells showed no similar apoptotic signs (Figure 3C
and D).
The sensitizing effects of NOXA are mediated by release
of Cyt C and smac into the cytosol
NOXA induces apoptosis through activation of Bax and/or Bak
to trigger mitochondrial dysfunction and caspase-9 activation
[10,11,27]. As expected, in cisplatin-sensitive A2780s cells, either
hNOXA or cisplatin alone resulted in significant up-regulation of
Bax and activation of caspases 3 and 9, and their combination
further enhanced the up-regulation of Bax and activation of the
caspases (figure 4A). Furthermore, the apoptosis was accompanied
by release of Cyt C and Smac into the cytosol (Figure 4B). Similar
results were also obtained in intrinsically resistant SKOV3 cells,
except that cisplatin alone was found not to cause the up-
regulation of Bax and activation of the caspases and release of Cyt
C and Smac (Figure 4A and B).
Alterations in the Bax/Smac axis determines sensitivity of
ovarian cancer cells to cisplatin
We observed that up-regulation of Bax and release of Smac into
the cytosol in NOXA-treated A2780s and SKOV3 cells (Figure 4),
and that cisplatin also led to Bax up-regulation and Smac release
in A2780s cells (Figure 4), but in SKOV3 cells, it did not caused
up-regulation of Bax (Figure 1 and 4) and release of Smac into the
cytosol (Figure 4). These observations prompted us to speculate
that Bax/Smac axis may be one of key determinants of
chemosensitivity in cisplatin-resistant ovarian cancer cells, and
that NOXA-induced alterations in the Bax/Smac Axis may
enhance sensitivity of ovarian cancer cells to cisplatin. To test the
speculation, we decided to investigate whether NOXA and/or
cisplatin-induced apoptosis was attenuated in cisplatin-sensitive
A2780s cells when treated with siRNA targeting Bax or Smac, and
whether NOXA and/or cisplatin-induced apoptosis was enhanced
in cisplatin-resistant SKOV3 cells when pretreated with Bax
construct or Smac N7 peptide, respectively.
As expected, Bax siRNA significantly attenuated NOXA and/
or cisplatin-induced apoptosis in A2780s cells (Figure 5A). Similar
results were also found in A2780s cells after treatment with siRNA
targeting Smac (Figure 5B). The specificity of Bax and Smac
siRNA duplexes was evaluated by analyzing Bax and Smac
protein expression in A2780s cells transfected with the corre-
sponding shRNA construction (Figure 5C). In pc3.1-Bax-trans-
fected SKOV3 cells, overexpression of Bax, which was confirmed
by western blotting analysis (Figure 5D), significantly increased
NOXA and/or cisplatin-induced apoptosis (Figure 5E). Similarly,
addition of an NH2-terminal Smac heptapeptide (Smac-N7) also
Figure 1. Genetic variants among the cisplatin-sensitive and -resistant ovarian cancer cells. (A) Western blotting was performed for the
expression variations of prosurvival Bcl-2, Bcl-xL and Mcl-1 and proapoptotic Bak and Bax proteins among the cisplatin-sensitive (A2780s, IGROV1 and
OAW42) and -resistant (A2780cp, OVCAR-3 and SKOV3) ovarian cancer cells. b-actin was used as a loading control. (B) A2780s (p53 WT) and SKOV3
(p53 -/-) cells were treated with cisplatin (5 mg/mL) for 24 hours and analyzed for the expression of p53, p73, p21
waf1/cip1, NOXA and Bax by Western
blotting. b-actin was used as a loading control. (C) OVCAR3 (harboring mutant p53 R248Q) and A2780cp (containing p53 wild-type gene sequence
but showing loss of p53 function) cells were treated with cisplatin (5 mg/mL) for 24 hours and analyzed for the expression of p53, p73, p21
waf1/cip1,
NOXA and Bax by Western blotting. b-actin was used as a loading control.
doi:10.1371/journal.pone.0036722.g001
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(Figure 5F).
Enhanced antitumor efficacy of the combination of
hNOXA and cisplatin in vivo
Based on the in vitro growth-inhibitory and pro-apoptotic effects
of hNOXA and cisplatin, we further examined the antineoplastic
effect of hNOXA plus cisplatin on A2780s and SKOV3 tumors in
vivo. As shown in figure 6A and B, on day 34 after implantation,
the A2780s and SKOV3 tumors of mice treated with PBS reached
1174.28670.43 and 823.82673.27 mm
3 in volume, respectively.
The A2780s and SKOV3 tumors treated with hNOXA were
significantly (A2780s model, P,0.001; SKOV3 model, P,0.001)
smaller than those treated with PBS, reaching only 686.06681.39
and 429.38622.9 mm
3 in volume, respectively. The combination
of hNOXA and cisplatin further suppressed tumor growth such
that the A2780s and SKOV3 tumors reached 342.84638.8 and
279.27647.16 mm
3 in volume, respectively, which were signifi-
cantly (A2780s model, P,0.001; SKOV3 model, P,0.001)
smaller than control tumors, and significantly smaller than the
tumors treated with hNOXA (A2780s model, P,0.001; SKOV3
model, p,0.05) or cisplatin (A2780s model, P,0.05; SKOV3
model, P,0.001). Cisplatin also resulted in a significant reduction
in tumor volume (577.08677.04 mm
3) compared with control
tumors (P,0.001) in the A2780s model. However, in SKOV3
model, no significant difference in tumor volume
(605.44680.51 mm
3) was observed in the cisplatin-treated group
compared with the pc3.1-treated group (695.57679.28 mm
3)
(P=0.222).
Survival curve analysis (Figure 6C) showed that A2780s tumor
bearing mice in the PBS or pc3.1-treated groups survived less than
65 days on average. By contrast, either hNOXA or cisplatin
resulted in a significant (P,0.05) increase in life span compared
with the two control groups, with the mean survival time being 74
and 80 days, respectively. The combination of hNOXA and
cisplatin further improved survival to a greater extent than the two
control groups (P,0.01), with the mean survival time being 87
days. Except that there was no significant difference in survival
time between cisplatin-treated mice and PBS-treated mice
(P=0.128) or pc3.1-treated mice (P=0.433), similar results were
also found in the SKOV3 tumor model (Figure 6D).
TUNEL was further performed to detect the apoptosis in tumor
tissues. In A2780s tumor model, hNOXA and/or cisplatin
increased the apoptotic rate of tumor cells when compared with
PBS or empty vector (Figure 6E and G). However, no significant
differences in the apoptotic index of tumors treated with the two
monotherapies were found in A2780s model (P=0.296). Similar
results were also found in SKOV3 tumor model, except that no
significant differences in apoptotic index were observed between
cisplatin-treated tumors and pc3.1-treated tumors (P=0.981) or
PBS-treated tumors (P=0.705) (Figure 6F and G).
The observations that hNOXA chemosensitized A2780s and
SKOV3 cells to cisplatin besides its antineoplastic effect in vivo
raised a question whether the enhanced antitumor efficacy
resulted from the delivery of hNOXA via tail vein injection. To
Figure 2. Reduced viability of ovarian cancer cells In Vitro by hNOXA and cisplatin. (A) RT-PCR analysis of hNOXA expression in vitro after
transfection of A2780s cells. GAPDH was used as a loading control. (B) Western blotting analysis of hNOXA expression in vitro after transfection of
A2780s cells. b-actin was used as a loading control. (C) The treatment of cisplatin at indicated concentrations and periods reduced A2780s cell
viability, showing that the dose of IC50 ranged from 5 mg/ml to 10 mg/ml. (D) The treatment of hNOXA plus cisplatin reduced A2780s cell viability
more significantly than the treatment of hNOXA alone or cisplatin alone did. Significant differences compared with the control group (24 h,
**P,0.001; 48 h,
##P,0.001). (E) The treatment of cisplatin alone had little effect on survival of SKOV3 cells, and the combination of hNOXA plus
cisplatin reduced SKOV3 cell viability more significantly than the treatment of hNOXA alone or cisplatin alone did. Significant differences compared
with the control group (24 h, **P,0.001; 48 h,
##P,0.001). Percentage of survival was calculated. Results are shown as means 6 SD of three wells
and triplicate experiments. In each experiment, the medium-only treatment (untreated) indicates 100% cell viability.
doi:10.1371/journal.pone.0036722.g002
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via tail vein injection actually gets to the tumor cells, RT-PCR was
performed. As expected, in vivo overexpression of exogenous
hNOXA was verified by RT-PCR in A2780s tumor tissues
(Figure 6H), indicating that intravenous injections of pc3.1-
hNOXA plasmid led to the expression of exogenous hNOXA
within the tumor tissues.
Discussion
NOXA, a ‘‘BH3-only’’ member of the Bcl-2 family, was shown
to be a target of p53 and/or p73-mediated transactivation [10,11].
NOXA first translocates to mitochondria and then functions
through Bax and/or Bak to induce apoptosis [10,11]. Recent
studies demonstrated that NOXA could induce apoptosis of some
cancer cells such as Hela epithelial cervical cancer cells [9],
melanoma cells [11], MCF-7 breast cancer cells [12], and
suggested a therapeutic potential in the treatment of human
breast cancer [12]. However, the role of NOXA in the therapeutic
responses of ovarian cancer cells to platinum-based anticancer
drugs remains unclear. The current study was designed to
investigate whether NOXA could induce apoptosis of ovarian
cancer cells, and whether it could potentiate antineoplastic effects
of cisplatin on ovarian cancer cells.
Many cancer cells express prosurvival Bcl-2 family proteins,
thereby rendering cells resistant to apoptosis [28,29]. Previous
studies have shown that Bcl-2 and Bcl-xL proteins appear to be
involved in chemoresistance in ovarian carcinoma [30–32], and
that reduced Bax expression is associated with cisplatin resistance
in ovarian carcinoma cell systems [33]. More recently, Bcl-xL and
Mcl-1 were reported to be able to cooperate to protect ovarian
carcinoma cells against oncogenic stress or chemotherapy-induced
apoptosis [34]. Consistent with these observations, our data
demonstrated that both relative high levels of Bcl-2, Bcl-xL and
Figure 3. Induction of apoptosis of tumor cells in vitro by hNOXA and cisplatin. (A) Representative DNA fluorescence histograms of PI-
stained cells. A2780s cells were treated with hNOXA for 24 h, then with 5 mg/ml cisplatin for an additional 24 h. A2780s cells were treated with
pcDNA3.1 or hNOXA, cisplatin alone or hNOXA plus cisplatin and groups Ctrl, pc3.1, hNOXA, Cis and hNOXA+Cis correspond to these five treatments
(the same as shown in the subsequent panels), with 8.7% (Ctrl), 15.6% (pc3.1), 34.6% (hNOXA), 48.3% (Cis) and 63.6% (hNOXA+Cis) sub-G1 cells
(apoptotic cells), respectively, as assessed by flow cytometry. (B) SKOV3 cells were treated with hNOXA for 24 h, then with 5 mg/ml cisplatin for an
additional 24 h. SKOV3 cells were untreated, treated with empty vector or hNOXA, cisplatin alone or hNOXA plus cisplatin, with 4.9% (Ctrl), 6.4%
(pc3.1), 38.4% (hNOXA), 9.1% (Cis) and 52.3% (hNOXA+Cis) sub-G1 cells (apoptotic cells), respectively, as assessed by flow cytometry. (C) Normal and
apoptotic nuclear morphology of A2780s cells was analyzed by Hoechst 33258 staining. A2780s cells were treated with the same conditions as
described above. (D) Normal and apoptotic nuclear morphology of SKOV3 cells was analyzed by Hoechst 33258 staining. SKOV3 cells were treated
with the same conditions as mentioned above.
doi:10.1371/journal.pone.0036722.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36722Mcl-1 and low levels of Bak and Bax are associated with the
chemoresistance of human ovarian cancer cells (Figure 1A). We
further found that p53, p21
waf1/cip1, which is indicative of
a functional p53, p73, NOXA and Bax were significantly induced
by cisplatin in p53-wild type A2780s cell line, but in other three
p53-mutant (SKOV3, OVCAR-3 and A2780cp) ovarian cancer
cell lines, the expressions of p73, p21
waf1/cip1, NOXA and Bax
remained unchanged (Figure 1B and C), indicating that the
responses of NOXA and Bax to cisplatin are regulated mainly by
p53 other than p73 in ovarian cancer cell lines.
Considering the major regulatory function of p53 on NOXA
and Bax, we then selected the p53 double deletion mutant
SKOV3 cell line as a model of intrinsic resistance, and the p53
wild-type A2780s cell line as a model of intrinsic chemosensitivity,
respectively, to evaluate the effect of NOXA on the chemother-
apeutic efficacy of cisplatin in vitro and in vivo. We found that
overexpression of hNOXA induced apoptosis and enhanced
sensitivity of both intrinsically cisplatin-sensitive A2780s and –
resistant SKOV3 cells to cisplatin, as evidenced by MTT assay
(Figure 2), flow cytometry analysis (Figure 3A and B), Hoechst
33258 staining (Figure 3C and D), activation of caspases 3 and 9
(Figure 4A) and release of Cyto c and Smac into the cytosol
(Figure 4B). Furthermore, the in vitro enhanced antiproliferative
and pro-apoptotic activities of hNOXA plus cisplatin on ovarian
cancer cells correlates well with the in vivo improved antitumor
efficacy. The enhanced antitumor efficacy in vivo was associated
with the enhanced induction of apoptosis, as verified by TUNEL
analysis (Figure 6).
Previous studies have shown that cisplatin-induced apoptosis
can be initiated through both intrinsic and extrinsic pathways.
Cisplatin induces rapid dose-dependent release of Cyt C from
mitochondria to cytosol [35]. Cyt C subsequently activates the
caspase cascade, eventually causing apoptotic cell death [36]. We
found that cisplatin induces apoptosis of chemosensitive A2780s
cells, but not chemoresistant SKOV3 cells. Furthermore, cisplatin-
induced apoptosis is associated with activation of caspase 3 and 9.
These observations are in agreement with previous reports that
caspase 3 and 9 are important for cisplatin-induced apoptosis, and
their activation is attenuated in resistant cells [37,38].
Figure 4. The sensitizing effects of hNOXA are mediated by enhanced caspase activation and release of Cyt C and Smac into the
cytosol. (A) A2780s and SKOV3 cells were subjected to the indicated treatments as described in Materials and Methods. Caspase activation were
analyzed by Western blotting. Arrows indicate active forms of caspases. b-actin was used as a loading control. (B) A2780s and SKOV3 cells were
subjected to the indicated treatments as described in Materials and Methods. Release of Cyt C and Smac into the cytosol were analyzed by Western
blotting. Cox-IV blots indicate mitochondrial loading controls while b-actin was used as a loading control for the cytosolic fraction.
doi:10.1371/journal.pone.0036722.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36722The key regulatory proteins of mitochondria-mediated apopto-
tosis are the Bcl-2 family of proteins, which can either promote cell
survival, as Bcl-2 and Bcl-xL do, or induce cell death, as Bax and
Bak do [39]. Bax plays a key role in mediating apoptosis induced
by certain anti-cancer agents [40]. Our data showed that cisplatin
induces up-regulation of Bax and release of mitochondrial Cyt c
and Smac into cytoplasm in chemosensitive A2780s cells, but not
in chemoresistant SKOV3 cells, whereas NOXA induces up-
regulation of Bax and release of mitochondrial Cyt c and Smac in
both A2780s and SKOV3 cells. These results is consistent with the
notion that Bax exerts at least part of its activity by triggering Cyt c
release from mitochondria [39].
Smac, also called direct inhibitor of apoptosis proteins (IAP)-
binding protein with low pI (Diablo), was also found to be released
into the cytosol of apoptotic cells [41]. Smac interacts with and
antagonizes IAPs, such as XIAP, cIAP1 and cIAP2 [41]. Recently,
Smac release is shown as a determinant of chemosensitivity in
ovarian cancer cells [42]. A previous report has shown that
TRAIL-induced apoptosis requires Bax-dependent mitochondrial
release of Smac/DIABLO [39]. Our recent publication has also
shown that Smac potentiates Bax activation, and that Smac-
mediated Bax activation is a major molecular event in AT101-
induced apoptosis in chemoresistant ovarian cancer cells [20].
These observations by us and others suggest an important role of
Bax/Smac axis in the apoptosis of cancer cells.
Figure 5. Alterations in the Bax/Smac Axis affect sensitivity of Ovarian Cancer Cells to Cisplatin. (A) siRNAs targeting Bax significantly
attenuated NOXA and/or cisplatin-induced apoptosis in chemosensitive A2780s cells (*P,0.01; **P,0.001). (B) siRNAs targeting Smac significantly
attenuated NOXA and/or cisplatin-induced apoptosis in chemosensitive A2780s cells (
#P,0.05; *P,0.01; **P,0.001). (C) Down-regulation of Bax or
Smac by Bax siRNA or Smac siRNA were confirmed by Western blot. (D) Overexpression of Bax was confirmed by Western blot. (E) SKOV3 cells were
co-transfected with NOXA and pc3.1-Bax plasmids for 12 hours, followed by 5 mg/mL cisplatin treatment for additional 12 hours. Overexpression of
Bax significantly increased NOXA and/or cisplatin-induced apoptosis in chemoresistant SKOV3 cells (*P,0.01). (F) SKOV3 cells were treated with
NOXA and/or cisplatin as described above, then with 20 mmol/L Smac-N7 peptide for an additional 3 hours. Smac-N7 peptide significantly increased
NOXA and/or cisplatin-induced apoptosis in chemoresistant SKOV3 cells (
#P,0.05; *P,0.01).
doi:10.1371/journal.pone.0036722.g005
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36722Figure 6. Enhanced antitumor efficacy of the combination of hNOXA and Cisplatin In Vivo (A–D) Tumor suppression and survival
advantage in mice. A2780s cells (A, C) or SKOV3 cells (B, D) of 2610
6 were inoculated subcutaneously into female nude mice at 6–8 weeks of age.
Mice (five per group) were treated with PBS, pcDNA3.1, pcDNA3.1-hNOXA, Cisplatin and pcDNA3.1-hNOXA+cisplatin. In A2780s tumor model,
significant differences in tumor suppression (**P,0.001) and survival time (
DP,0.05) in mice treated with hNOXA or cisplatin versus PBS and
pcDNA3.1 controls; significant difference for tumors treated with hNOXA+cisplatin versus PBS and pcDNA3.1 controls (**P,0.001;
DDP,0.01), and
significant difference for the combination therapy versus hNOXA or cisplatin monotherapy (
#P,0.05;
{P,0.05). Similar results were also found in
SKOV3 model, except that no significant differences in tumor suppression (P=0.222) and survival time (P=0.433) between cisplatin- and pcDNA3.1-
treated tumors were found. (E–F) TUNEL staining of tumor tissues. Representative sections were taken from A2780s (E) and SKOV3 (F) tumor tissues
of mice receiving PBS, pcDNA3.1, hNOXA, cisplatin and hNOXA+cisplatin. (G) Apoptotic index within A2780s and SKOV3 tumor tissues were counted.
In A2780s model, statistically significant difference in the apoptotic index for tumors treated with hNOXA or cisplatin versus PBS and pcDNA3.1
controls (**P,0.001); significant difference for tumors treated with hNOXA+cisplatin versus the two controls (**P,0.001); and significant difference
for the combination therapy versus hNOXA or cisplatin monotherapy (
##P,0.001). Similar results were also found in SKOV3 model, except that no
significant differences in the apoptotic index between cisplatin-treated tumor and pcDNA3.1-treated tumor (P=0.981) or PBS-treated tumor
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36722Taken together, we speculated that NOXA enhance sensitivity
of ovarian cancer cells to cisplatin by inducing alterations in the
Bax/Smac Axis. The speculation was supported by our findings as
follows: siRNAs targeting Bax or Smac significantly attenuated
NOXA and/or cisplatin-induced apoptosis in chemosensitive
A2780s cells (Figure 5A and B), whereas overexpression of Bax
or addition of an NH2-terminal Smac heptapeptide (Smac-N7)
significantly increased NOXA and/or cisplatin-induced apoptosis
in chemoresistant SKOV3 cells (Figure 5 E and F). Our results are
similar to previous reports that cisplatin-induced apoptosis in
ovarian cancer cells depends on efficient Bax expression [7], and
that SMAC expression and agents that mimic the IAP interacting
function of SMAC sensitize human cancer cells to apoptosis
induced by several anticancer agents, such as tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) and TNF alpha
[43,44].
In conclusion, our data suggest that elevated expression of
NOXA can induce apoptosis independently of p53 in both
cisplatin-sensitive A2780s (p53WT) and cisplatin-resistant SKOV3
(p53 -/-) ovarian cancer cells, and that it can enhance the
therapeutic responses of ovarian cancer, especially the intrinsically
resistant, p53 double deletion mutant ovarian cancer cells, to
cisplatin by inducing alterations in the Bax/Smac axis. To our
knowledge, we provide the first evidence for the potential
application of NOXA as a chemosensitizer in ovarian cancer
therapy.
Acknowledgments
The authors thank Dr. David Huang for providing pc3.1-hNoxa
expression plasmid, and Dr. Bing Kan and Yong-qiu Mao for their
technical support.
Author Contributions
Conceived and designed the experiments: CN ZY. Performed the
experiments: CL XZ L. Li CN ZY. Analyzed the data: CN ZY YW.
Contributed reagents/materials/analysis tools: HL KC YW XL L. Liu AT
HD JL. Wrote the paper: CL ZY.
References
1. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, et al. (2005)
Current concepts of treatment strategies in advanced or recurrent ovarian
cancer. Oncology 68: 293–298.
2. Folkman J (1995) Seminars in medicine of the Beth Israel Hospital, Boston:
Clinical applications of research on angiogenesis. N Engl J Med 333:
1757–1763.
3. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer
genetics and chemotherapy. Cell 108: 153–164.
4. Yu J, Zhang L (2004) Apoptosis in human cancer cells. Curr Opin Oncol 16:
19–24.
5. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, et al. (2001)
Correlation of p53 Mutations with Resistance to Platinum-based Chemotherapy
and Shortened Survival in Ovarian Cancer. Clin cancer Res 7: 2984–2997.
6. Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, et al. (2011) P73
regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/
calpain-dependent mechanism, Oncogene 30: 4219–4230.
7. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, et al. (2008)
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in
cisplatin-resistant ovarian cancer cells, Mol Cancer Ther 7: 1410–1419.
8. Ibrahim N, He L, Leong CO, Xing D, Karlan BY, et al. (2010) BRCA1-
Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for
Chemosensitivity in Ovarian Carcinoma, Cancer Res 70: 7155–7165.
9. Seo YW, Shin JN, Ko KH, Cha JH, Park JY, et al. (2003) The molecular
mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell
death. J Biol Chem 278: 48292–48299.
10. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3-
only member of the Bcl-2 family and candidate mediator of p53-induced
apoptosis. Science 288: 1053–1058.
11. Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, et al.
(2008) The BH3-only member Noxa causes apoptosis in melanoma cells by
multiple pathways. Oncogene 27: 4557–4568.
12. Suzuki S, Nakasato M, Shibue T, Koshima I, Taniguchi T (2009) Therapeutic
potential of proapoptotic molecule Noxa in the selective elimination of tumor
cells. Cancer Sci 100: 759–769.
13. Debernardis D, Sire ´ EG, De Feudis P, Vikhanskaya F, Valenti M, et al. (1997)
p53 status does not affect sensitivity of human ovarian cancer cell lines to
paclitaxel. Cancer Res. 57: 870–874.
14. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Sire ´ E, et al.
(1997) DDP-induced cytotoxicity is not influenced by p53 in nine human
ovarian cancer cell lines with different p53 status, Br J Cancer. 76: 474–479.
15. Gallardo D, Drazan KE, McBride WH (1996) Adenovirus-based transfer of
wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56:
4891–4893.
16. Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, et al. (2007) Absence of
Bcl-xL down-regulation in response to cisplatin is associated with chemoresis-
tance in ovarian carcinoma cells. Gynecol Oncol 105: 31–44.
17. Sasaki H, Sheng Y, Kotsuji F, Tsang BK (2000) Down-regulation of X-linked
inhibitor of apoptosis protein induces apoptosis in chemoresistant human
ovarian cancer cells. Cancer Res 60: 5659–5666.
18. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, et al. (2005) Expression
of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent
disease. Gynecol Oncol 96: 287–295.
19. Yuan Z, Liu H, Yan F, Wang Y, Gou L, et al. (2009) Improved therapeutic
efficacy against murine carcinoma by combining honokiol with gene therapy of
PNAS-4, a novel pro-apoptotic gene. Cancer Sci 100: 1757–1766.
20. Hu W, Wang F, Tang J, Liu X, Yuan Z, et al. (2012) Pro-apoptotic protein,
smac, mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated
with the anti-tumor agent, AT101, J Biol Chem 287: 68–80.
21. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, et al. (1999) Systemic
inhibition of tumor growth and tumor metastases by intramuscular administra-
tion of the endostatin gene. Nat Biotechnol 17: 343–348.
22. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, et al. (2008) Down-regulation
of phospho-Akt is a major molecular determinant of bortezomib-induced
apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698–6707.
23. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, et al. (1994) Induction
of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 54:
4952–4957.
24. Ruiz-Vela A, Opferman JT, Cheng EH, Korsmeyer SJ (2005) Proapoptotic
BAX and BAK control multiple initiator caspases. EMBO Rep 6: 379–385.
25. Leu JI, Dumont P, Hafey M, Murphy ME, George DL (2004) Mitochondrial
p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6:
443–450.
26. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL (2000) Adenovirus-
mediated gene transfer of endostatin in vivo results in high level of transgene
expression and inhibition of tumor growth and metastases. Proc Natl Acad
Sci U S A 97: 4802–4807.
27. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, et al. (2002)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis,
serving as prototype cancer therapeutics. Cancer Cell 2: 183–192.
28. Daniel NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:
205–219.
29. Labi V, Erlacher M, Kiessling S, Villunger A (2006) BH3-only proteins in cell
death ignition, malignant disease and anticancer therapy. Cell Death Diff 13:
1325–1338.
30. Kassim SK, Ali HS, Sallam MM, Fayed ST, Seada LS, et al. (1999) Increased
bcl-2 expression is associated with primary resistance to chemotherapy in human
epithelial ovarian cancer. Clin Biochem 32: 333–338.
31. Liu JR, Fletcher B, Page C, Hu C, Nunez G, et al. (1998) Bcl-xL is expressed in
ovarian carcinoma and modulates chemoterapy-induced apoptosis. Gynecol
Oncol 70: 398–403.
32. Dodier P, Piche ´ A (2006) Bcl-X(L) is functionally non-equivalent for the
regulation of growth and survival in human ovarian cancer cells. Gynecol Oncol
100: 254–63.
33. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, et al. (1996)
Association between cisplatin resistance and mutation of p53 gene and reduced
bax expression in ovarian carcinoma cell systems, Cancer Res. 56: 556–562.
34. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, et al. (2009) Mcl-1 is an
important determinant of the apoptotic response to the BH3-mimetic molecule
(P=0.705) were found. The apoptotic index was calculated as a ratio of the apoptotic cell number to the total cell number in each field. (H) RT-PCR
analysis of expression of exogenous hNOXA in vivo.
doi:10.1371/journal.pone.0036722.g006
NOXA-Induced Alterations in Bax/Smac Axis
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36722HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 8:
3162–3170.
35. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, et al. (2006)
Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion
channel protein in the mitochondrial membrane of head and neck squamous cell
carcinoma: possible role in apoptosis. Clin Cancer Res 12: 5817–5825.
36. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, et al. (1997)
Cytochrome C and dATP-dependent formation of Apaf-1/caspase-9 complex
initiates an apoptotic protease cascade. Cell 91: 479–489.
37. Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and caspase-
3-dependent cleavage during cisplatin-induced apoptosis in human ovarian
epithelial cancer cells. Cancer Res 61: 1862–1868.
38. Henkels KM, Turchi JJ (1999) Cisplatin-induced apoptosis proceeds by caspase-
3-dependent and -independent pathways in cisplatin-resistant and -sensitive
human ovarian cancer cell lines. Cancer Res 59: 3077–3083.
39. Deng Y, Lin Y, Wu X (2002) TRAIL-induced apoptosis requires Bax-dependent
mitochondrial release of Smac/DIABLO. Genes Dev 16: 33–45.
40. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in the
apoptotic response to anticancer agents. Science 290: 989–992.
41. Yu J, Wang P, Ming L, Wood MA, Zhang L (2007) SMAC/Diablo mediates the
proapoptotic function of PUMA by regulating PUMA-induced mitochondrial
events, Oncogene 26: 4189–4198.
42. Yang X, Fraser M, Moll UM, Basak A, Tsang BK (2006) Akt-mediated cisplatin
resistance in ovarian cancer: modulation of p53 action on caspase-dependent
mitochondrial death pathway, Cancer Res 66: 3126–3136.
43. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for
Apo2L/TRAIL- or anticancer druginduced apoptosis and induce regression of
malignant glioma in vivo. Nat Med 8: 808–815.
44. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, et al. (2004) A small
molecule Smac mimic potentiates TRAIL- and TNF alpha-mediated cell death.
Science 305: 1471–1474.
NOXA-Induced Alterations in Bax/Smac Axis
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36722